Ben-Noon Alon purchased $200K of NRSN

Ben-Noon Alon (Chief Executive Officer) purchased 250,000 shares of NeuroSense Therapeutics Ltd. (NRSN) at $0.80 ($0.20M total) on 2026-06-16.

Original reporting
SEC EDGAR · Ben-Noon Alon
Published Jun 17, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NRSN
Bullish
medium confidence
Mentioned
$NRSN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRSNBullishLow
01

Why it matters

This provides a fresh datapoint on insider sentiment (CEO buying) but does not disclose any new business milestone, clinical result, or financing terms.

02

Market read

Traders may treat the CEO buy as a small positive sentiment input, but it is unlikely to be a primary driver without additional catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; traders may still discount signal strength because insider purchases are not the same as new guidance or trial/regulatory outcomes.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-17; transaction dated 2026-06-16.

Background

The article is an SEC Form 4 insider transaction disclosure for NeuroSense Therapeutics, showing an open-market purchase by the CEO.

Company-level read

Ticker impact

$NRSNBullishMedium confidence
Context

NeuroSense Therapeutics CEO Ben-Noon Alon filed a Form 4 open-market purchase of 250,000 shares at $0.80 on 2026-06-16.

Expected impact

Likely limited near-term impact; any reaction should fade unless follow-on news (financing, trial, guidance) emerges.

Evidence & confidence

The article is a primary insider transaction disclosure (Form 4) with clear size and price, but it does not include new operating/clinical/regulatory catalysts.

Market effects

No sector-wide read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

CEO buying can be driven by diversification, liquidity needs, or routine compensation-related behavior rather than a strong forward outlook.

Key entities

  • NeuroSense Therapeutics Ltd.

    Subject of the Form 4 insider transaction; CEO purchased 250,000 shares at $0.80.

  • Ben-Noon Alon

    CEO who reported the open-market purchase; holdings after transaction: 4,534,233 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NRSNMedAI 8/10

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

NeuroSense Therapeutics (NRSN) plans to include new neurofilament light chain (NfL) data in its New Drug Submission (NDS) for PrimeC, its ALS treatment, to Health Canada. The filing, now targeted for March 2027, aims to strengthen the application with additional biomarker evidence. If approved, PrimeC could address approximately 4,000 Canadians living with ALS. The company is also advancing discussions with potential commercialization partners for Canada.

$NRSNHighAI 9/10

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

NeuroSense Therapeutics (NASDAQ: NRSN) will present clinical and biomarker data from its PARADIGM Phase 2b program at the 2026 NEALS Annual Meeting. The findings will inform the development strategy for its planned Phase 3 study (PARAGON) of PrimeC, a treatment for ALS. The company has received FDA clearance to initiate the PARAGON trial, which is designed to be more rigorous and efficient based on the PARADIGM results.

$NRSNMed

NeuroSense Therapeutics Ltd. (NRSN): Financial results for H1 2026

NeuroSense Therapeutics Ltd. (NRSN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., September 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-

$NRSNMedAI 8/10

NeuroSense Unveils Accelerated, Capital-Efficient PrimeC Development Strategy In ALS

NeuroSense Therapeutics (NRSN) announced a redesigned development strategy for PrimeC in ALS, aiming to accelerate regulatory approval and reduce costs. The strategy includes AI-enabled formulation analysis, a comparative study against edaravone, and an optimized Phase 3 trial design. The company has received FDA clearance and is targeting a Canadian regulatory submission by December 2026. PrimeC is an investigational oral therapy combining ciprofloxacin and celecoxib.

$NRSNHighAI 9/10

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NeuroSense Therapeutics (NASDAQ: NRSN) said its Phase 2b PARADIGM trial of PrimeC in ALS met the primary endpoint: at Day 180, TDP-43 fell vs placebo (p=0.0421), with differences sustained at Day 540 (p<0.001). The company also reported slower ALSFRS-R decline and a median survival benefit (HR 0.35, p=0.004), plus no new safety signals, and said FDA clearance was obtained for Phase 3.